TITLE:
Hypercoagulability in the Context of Pre-Eclampsia: Case-Control Study at the Laquintinie Douala Hospital (Cameroon)
AUTHORS:
Henri Essome, Marie Solange Ndom Idjem, Théophile Nana Njamen, Thomas Egbe Obinchemti, Merlin Boten, Grace Tocki Toutou, Grégory Eddie Halle, Guy Pascal Ngaba, Pascal Foumane
KEYWORDS:
Preeclampsia, Hypercoagulability, Prothrombin, Cephalin, Lacintinia
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.10 No.12,
December
25,
2020
ABSTRACT: Introduction: Preeclampsia is one of the major causes of maternal
and neonatal morbidity and mortality in the world. The
complexity of its etio-pathogenesis involves, among other things, hypercoagulability, which alone accounts for
about 15% of his deaths. Our objective was to study the parameters of
coagulation (prothrombin level, activated cephalin time) in pregnant women with
preeclampsia and non-preeclampsia at Laquintinie Hospital in Douala. Methodology: We carried out an analytical cross-sectional case-control study from November
01st, 2018 to May 31st, 2019, in the gynecology and
obstetrics department of Laquintinie Hospital in Douala. We included
preeclampsia and non-preeclampsia pregnant women with a gestational age greater
than or equal to 20 weeks amenorrhea. The variables of interest were age,
pregnancy, parity, gestational age, marital status and body mass index, prothrombin level (PL) and activated cephalin time (ACT). Hypercoagulability was defined
by the presence of at least one of the following abnormalities: PL > 100%, ACT 25 seconds. Statistical tests were considered
significant for a p-value 0.05. Results: We recruited 150 pregnant women including 50
preeclampsia matched with 100 non-preeclampsia. The majority age group
in both groups was 25 - 30 years (32% versus 37%).
We found a high PL in 58% of preeclampsia versus 22% of non-preeclampsia
patients (p = - 10.20; p = Conclusion: Our study confirms the existence of hypercoagulability associated with
preeclampsia, in particular in relation to an increase in the level of prothrombin.